L-leucine.

L-leucine is the precursor from which the body makes HMB, and HMB carries much of leucine's effect on limiting muscle protein breakdown. Pairing them supplies the synthesis signal from leucine and the breakdown signal from HMB directly.

L-leucine competes with valine and isoleucine for the same LAT1 transporter and the same aminotransferase step, so leucine on its own pulls the other two down in plasma. Including valine keeps the branched-chain amino acid pool in proportion.

Branched chain aminotransferase, the first step of leucine catabolism, runs on pyridoxal phosphate. Cofactor status governs how leucine nitrogen is handed to glutamate.

The branched chain ketoacid dehydrogenase complex needs thiamine pyrophosphate for its decarboxylation step. Leucine oxidation stalls at the ketoacid without it.

FAD from riboflavin serves the dehydrogenase complex and the acyl-CoA dehydrogenase step downstream in leucine breakdown. Riboflavin supply sets the flux through those steps.

Lipoamide is the covalently bound cofactor of the E2 core of branched chain ketoacid dehydrogenase, the same role it plays in pyruvate dehydrogenase. It carries the acyl group during leucine oxidation.

Leucine catabolism runs through isovaleryl-CoA and HMG-CoA, both of which need coenzyme A built from pantothenate. Without CoA the pathway has no carrier for its intermediates.

3-methylcrotonyl-CoA carboxylase is a biotin dependent enzyme and sits on the leucine only branch of branched chain catabolism. It is the step that makes leucine handling distinctly biotin sensitive.

Glutamine efflux on SLC1A5 drives leucine entry through the LAT1 antiporter, so glutamine availability shapes intracellular leucine. Glutamine also carries away the nitrogen leucine transamination releases.

Leucine and tryptophan compete for the same large neutral amino acid carrier at the blood brain barrier. A leucine load lowers central tryptophan uptake, which is the basis of the classic branched chain interaction.

Tyrosine crosses into the brain on the same LAT1 carrier that leucine uses, so the two compete. A high leucine dose reduces the tyrosine fraction reaching central tissue.

Vitamin D receptor signalling in muscle acts on the same protein synthesis machinery that leucine switches on through mTORC1. The two inputs converge on one output from different directions.

The amino group stripped from leucine in muscle leaves largely as alanine and glutamine through the glucose-alanine cycle. Alanine is the vehicle for that nitrogen rather than a competitor.

Leucine, isoleucine and valine share branched-chain aminotransferase and the branched-chain ketoacid dehydrogenase complex, and they compete for the LAT1 transporter at the gut and the blood-brain barrier. A large isolated leucine dose lowers circulating isoleucine and valine, which is why blends use a fixed ratio rather than leucine alone. The relationship is competitive at the transporter and shared at the enzyme. Both facts belong in a formulation decision.

Leucine acts as the trigger that switches on mTORC1 signalling, but building new protein still requires every other amino acid as substrate. Whey supplies both, which is why added leucine on top of a whey serve has less to add than leucine on top of a low-protein meal. The pairing matters most where total protein intake is modest. That framing is standard sports-nutrition practice rather than a trial result.

Casein produces a low, extended rise in plasma amino acids while free leucine produces a sharp early peak. Formulas combine them to get an early signalling spike and a longer substrate supply from one serve. The kinetics of each are well characterised separately. The combined shape is inference from those kinetics. Read it as mechanistic rather than as a measured outcome.

Creatine raises phosphocreatine availability and supports the ability to complete training volume, while leucine signals the protein synthesis machinery after that training. The two act at different points and are routinely stacked for that reason. Trials of the combination as a fixed pair are not what establishes it. The separate literatures for each are. The additive framing is mechanistic.

LAT1 is a saturable exchanger with a limited number of sites, and a large leucine bolus reduces the transport of other large neutral amino acids including phenylalanine across the gut wall and the blood-brain barrier. This is the same competition that underlies the classic tryptophan and tyrosine displacement effect. It is a dosing and timing consideration, not a safety statement. Splitting doses keeps the competition mild.

Methionine is a LAT1 substrate and competes with leucine for the same carrier sites when both arrive at once. The result is a lower absorbed peak for whichever is present in the smaller amount. In a mixed protein meal this competition is already the normal state of affairs. It becomes visible only when one free amino acid is dosed in isolation.

Histidine shares LAT1 transport with the branched-chain amino acids, so a concentrated free-leucine dose reduces its transported fraction over the same window. The effect is transient and tracks the plasma leucine peak. It is worth knowing where free amino acids are dosed separately across a day. Whole protein blunts the whole issue.

Long-chain omega-3 fatty acids incorporate into muscle cell membranes and have been reported to increase the sensitivity of the anabolic signalling response to an amino acid load. Findings have measured signalling and synthesis rates, which are markers of process rather than change in function. The size and consistency of the effect are still unsettled. The pairing is common in older-adult formulas on that basis.

Leucine degradation generates acyl-CoA intermediates, and carnitine is the shuttle that moves acyl groups across the mitochondrial membrane, buffering the free CoA pool. High branched-chain amino acid loads shift the acylcarnitine profile, which is a metabolic marker measured in plasma. This is biochemistry rather than a supplementation claim. It is why acylcarnitines are used to read branched-chain amino acid flux.

The rate-limiting step of leucine catabolism is controlled by a kinase and a phosphatase acting on the branched-chain ketoacid dehydrogenase complex, and the kinase runs on magnesium-ATP. Magnesium status therefore sits underneath the regulation of leucine breakdown. This is settled cofactor chemistry and not an argument for co-dosing. It explains why magnesium appears in general amino acid formulas.

Betaine acts as an osmolyte and a methyl donor, while leucine acts on translation initiation signalling. Sports formulas combine them because the mechanisms do not overlap or interfere. No trial isolates the pair. The row records a common formulation shape, not a demonstrated effect.

Collagen peptides are rich in glycine, proline and hydroxyproline and poor in the branched-chain amino acids. Added leucine supplies the signalling trigger that collagen alone does not, which is why some connective-tissue formulas fortify collagen with leucine. Composition is a fact of the protein, not a trial finding. The functional consequence of the combination has not been isolated.

Taurine acts as a cellular osmolyte and calcium-handling modulator, while leucine acts on translational signalling. The two are combined because neither interferes with the other and both are stable in the same matrix. There is no combination evidence. This is formulation practice.

Both leucine and arginine stimulate insulin release from pancreatic beta cells through separate routes, leucine by allosteric activation of glutamate dehydrogenase and arginine by depolarisation. The consequence is a larger post-dose insulin excursion than either alone would give, which is a measured marker and not a clinical endpoint. Anyone tracking glucose response should know the combination moves it. The magnitude for this specific pair has not been characterised.